'ZDNET Recommends': What exactly does it mean?
ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources, including vendor and retailer listings as well as other relevant and independent reviews sites. And we pore over customer reviews to find out what matters to real people who already own and use the products and services we’re assessing.
When you click through from our site to a retailer and buy a product or service, we may earn affiliate commissions. This helps support our work, but does not affect what we cover or how, and it does not affect the price you pay. Neither ZDNET nor the author are compensated for these independent reviews. Indeed, we follow strict guidelines that ensure our editorial content is never influenced by advertisers.
ZDNET's editorial team writes on behalf of you, our reader. Our goal is to deliver the most accurate information and the most knowledgeable advice possible in order to help you make smarter buying decisions on tech gear and a wide array of products and services. Our editors thoroughly review and fact-check every article to ensure that our content meets the highest standards. If we have made an error or published misleading information, we will correct or clarify the article. If you see inaccuracies in our content, please report the mistake via this form.
Two OTC continuous glucose monitors won awards at CES - and you can try them now
Abbott and Dexcom, who announced consumer over-the-counter continuous glucose monitors (CGM) in 2022 and 2024, respectively, launched their CGM devices for public purchase at CES 2025. Many people with diabetes and insulin-related health issues struggle to find accessible and affordable care, making these products a potential game changer in the healthcare sphere.
Also: CES 2025: The 17 most impressive products you don't want to miss
People without diabetes also use glucose monitoring to help make adjustments to their eating habits and improve overall health. So, Abbott's Lingo and the Stelo by Dexcom could benefit a wide variety of users.
Stelo by Dexcom tracks glucose levels 24/7
This CGM is designed for general wellness tracking but Dexcom emphasizes it was also designed to empower those with Type 2 diabetes who are not on insulin and prediabetics who are 18 years or older. The sensor, a "small, flexible wire," is inserted under your skin by an applicator and tracks glucose levels 24/7. The device comes with two sensors, each one lasts up to 15 days and connects to an app on your iPhone or Android that delivers your readings.
Also: The Best of CES 2025 awards are in, as selected by ZDNET and the rest of CNET Group
Previously, the company sold similar devices, but they were much more expensive and sometimes involved insurance for them to be accessible.
You can order the Stelo Glucose Biosensor at $89 a month or for a one-time purchase of $99. Use of its app requires a minimum of iOS 16.2 or Android 12. Stelo also offers FSA or HSA reimbursements, but check for eligibility.
Lingo monitors for general wellness
Abbott's Lingo is very similar to the Stelo, however the Lingo has a wear span of 14 days. This device also requires users to be 18 or older and to not be on insulin. It uses your glucose data to make personalized suggestions helping you get a better grip on your lifestyle. It offers coaching, a companion app, and personal insights on eating habits, stressors, and exercise.
This device is also inserted into your arm using a thin, flexible filament via an applicator, but the website says that most people find the process painless. Lingo's app is iOS only, so the service is only offered to iPhone users for now.
Also: I wore a continuous glucose monitor for a month. Here's what I learned
The Lingo consumer CGM monitor is available now at three pricing tiers: A 2-week plan at $49, a 4-week plan at $89, and a 12-week subscription at $249.
Both Abbott's Lingo and the Stelo by Dexcom were Honorees in Digital Health at CES 2025.